KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Assets: 2018-2024

Historic Non-Current Assets for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $171.1 million.

  • Castle Biosciences' Non-Current Assets rose 20.86% to $205.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.2 million, marking a year-over-year increase of 20.86%. This contributed to the annual value of $171.1 million for FY2024, which is 8.48% up from last year.
  • Castle Biosciences' Non-Current Assets amounted to $171.1 million in FY2024, which was up 8.48% from $157.7 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' Non-Current Assets ranged from a high of $171.1 million in FY2024 and a low of $9.7 million during FY2020.
  • Its 3-year average for Non-Current Assets is $161.3 million, with a median of $157.7 million in 2023.
  • Data for Castle Biosciences' Non-Current Assets shows a peak YoY skyrocketed of 1,018.03% (in 2021) over the last 5 years.
  • Over the past 5 years, Castle Biosciences' Non-Current Assets (Yearly) stood at $9.7 million in 2020, then skyrocketed by 1,018.03% to $108.8 million in 2021, then soared by 42.46% to $155.0 million in 2022, then grew by 1.72% to $157.7 million in 2023, then rose by 8.48% to $171.1 million in 2024.